Document Detail

Epididymitis after transrectal ultrasound-guided needle biopsy of prostate gland.
MedLine Citation:
PMID:  14972477     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate the incidence, predisposing factors, and time-course of epididymitis after transrectal ultrasound-guided (TRUS) needle biopsy of the prostate gland. METHODS: A total of 739 consecutive patients underwent TRUS-guided biopsy of the prostate gland from January 2000 through December 2002 using a systematic approach, 18-gauge needles, and antibiotic prophylaxis. A median of 9 biopsies was obtained per patient (range 4 to 16). All cases of epididymitis occurring within 6 months of biopsy were attributed to the TRUS procedure. The parameters evaluated for epididymitis included patient age, prostate-specific antigen, prostate volume, prostate-specific antigen density, number of biopsies obtained, and number of biopsies positive for malignancy. RESULTS: Five patients (0.7%) developed biopsy-related epididymitis with a median onset of 85 days (range 13 to 143) after biopsy. Patients developing epididymitis were statistically older, with a trend for a greater number of prostate biopsies (P = 0.071 on linear regression analysis). Only 1 patient developed epididymitis within 3 weeks of biopsy. All cases of epididymitis responded to therapeutic antibiotics. CONCLUSIONS: Epididymitis after TRUS-guided biopsy is a relatively uncommon event, with an incidence of approximately 1% and an onset of weeks to months after the procedure. Patients who developed epididymitis were statistically older, with a trend for a greater number of prostate biopsies taken.
Joseph G Donzella; Gregory S Merrick; David J Lindert; Hugo J Andreini; Rodney L Curtis; Ignacio H Luna; Zachariah Allen; Wayne M Butler
Related Documents :
20575597 - Low serological positivity in patients with histology compatible with celiac disease in...
19253357 - Sonographic features of traumatic neuromas after neck dissection.
21718497 - Predictive equations not always overestimate the resting energy expenditure in amyotrop...
17689647 - Cervical adenocarcinoma in situ: the predictive value of conization margin status.
20176597 - Increased serum insulin-like growth factor 1 in early idiopathic parkinson's disease.
24488387 - Serum soluble-fas is a predictor of red blood cell transfusion in critically ill patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Urology     Volume:  63     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-02-19     Completed Date:  2004-06-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  306-8     Citation Subset:  IM    
Men's Health Center, Wheeling Hospital, Wheeling, West Virginia 26003-6300, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anti-Bacterial Agents / therapeutic use
Antibiotic Prophylaxis
Biopsy, Needle / adverse effects*,  methods
Ciprofloxacin / therapeutic use
Disease Susceptibility
Epididymitis / drug therapy,  epidemiology,  etiology*,  prevention & control
Follow-Up Studies
Middle Aged
Ofloxacin / therapeutic use
Prostate / pathology*
Ultrasonography, Interventional* / methods
Reg. No./Substance:
0/Anti-Bacterial Agents; 82419-36-1/Ofloxacin; 85721-33-1/Ciprofloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Optimal combinations for detection of prostate cancer: systematic sextant and laterally directed bio...
Next Document:  Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for pro...